Neurocrine Historical Income Statement

NBIX Stock

USD 126.59 1.32 1.03%

Historical analysis of Neurocrine Biosciences income statement accounts such as Total Revenue of 2 B can show how well Neurocrine Biosciences performed in making a profits. Evaluating Neurocrine Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Neurocrine Biosciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Neurocrine Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neurocrine Biosciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

About Neurocrine Income Statement Analysis

Neurocrine Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Neurocrine Biosciences shareholders. The income statement also shows Neurocrine investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Neurocrine Biosciences Income Statement Chart

At this time, Neurocrine Biosciences' Total Operating Expenses is fairly stable compared to the past year. Income Before Tax is likely to rise to about 348.7 M in 2024, whereas Cost Of Revenue is likely to drop slightly above 38.9 M in 2024.

Interest Expense Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Selling And Marketing Expenses

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Neurocrine Biosciences. It is also known as Neurocrine Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Neurocrine Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Total Operating Expenses is fairly stable compared to the past year. Income Before Tax is likely to rise to about 348.7 M in 2024, whereas Cost Of Revenue is likely to drop slightly above 38.9 M in 2024.

Neurocrine Biosciences income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Reconciled Depreciation	Tax Provision	Non Recurring
Depreciation And Amortization		0.99	0.99	0.99	1.0	0.81	0.87	0.99	0.88	-0.05	1.0	0.93	0.27	0.75	0.28	-0.77	0.67	-0.68	0.89	-0.23	0.92	0.2	-0.85
Selling General Administrative	0.99		0.99	0.99	0.99	0.83	0.88	0.99	0.89	-0.15	0.99	0.89	0.19	0.74	0.23	-0.68	0.68	-0.63	0.94	-0.36	0.93	0.15	-0.85
Total Revenue	0.99	0.99		1.0	0.99	0.87	0.92	0.99	0.93	-0.11	0.99	0.93	0.18	0.8	0.18	-0.71	0.74	-0.67	0.93	-0.34	0.93	0.1	-0.82
Gross Profit	0.99	0.99	1.0		0.99	0.88	0.92	0.99	0.93	-0.12	0.99	0.93	0.18	0.8	0.18	-0.7	0.74	-0.67	0.94	-0.35	0.93	0.1	-0.82
Other Operating Expenses	1.0	0.99	0.99	0.99		0.8	0.86	1.0	0.87	-0.08	1.0	0.91	0.27	0.74	0.27	-0.75	0.66	-0.66	0.91	-0.28	0.92	0.19	-0.85
Operating Income	0.81	0.83	0.87	0.88	0.8		0.99	0.79	0.99	-0.22	0.8	0.87	-0.16	0.92	-0.14	-0.44	0.91	-0.61	0.88	-0.5	0.81	-0.2	-0.58
Ebit	0.87	0.88	0.92	0.92	0.86	0.99		0.85	1.0	-0.17	0.86	0.92	-0.04	0.93	-0.07	-0.56	0.9	-0.64	0.89	-0.44	0.85	-0.13	-0.64
Research Development	0.99	0.99	0.99	0.99	1.0	0.79	0.85		0.86	-0.07	1.0	0.9	0.27	0.73	0.25	-0.73	0.66	-0.67	0.9	-0.27	0.92	0.17	-0.85
Ebitda	0.88	0.89	0.93	0.93	0.87	0.99	1.0	0.86		-0.16	0.87	0.92	-0.03	0.92	-0.06	-0.57	0.9	-0.65	0.9	-0.43	0.85	-0.12	-0.65
Cost Of Revenue	-0.05	-0.15	-0.11	-0.12	-0.08	-0.22	-0.17	-0.07	-0.16		-0.08	0.03	0.38	-0.11	0.22	-0.21	-0.18	-0.16	-0.36	0.7	-0.07	0.25	-0.07
Total Operating Expenses	1.0	0.99	0.99	0.99	1.0	0.8	0.86	1.0	0.87	-0.08		0.91	0.27	0.74	0.26	-0.75	0.66	-0.66	0.91	-0.28	0.92	0.18	-0.85
Income Before Tax	0.93	0.89	0.93	0.93	0.91	0.87	0.92	0.9	0.92	0.03	0.91		0.28	0.84	0.23	-0.74	0.78	-0.71	0.78	-0.14	0.87	0.16	-0.78
Total Other Income Expense Net	0.27	0.19	0.18	0.18	0.27	-0.16	-0.04	0.27	-0.03	0.38	0.27	0.28		0.06	0.37	-0.57	-0.02	-0.19	-0.07	0.49	0.14	0.33	-0.4
Net Income	0.75	0.74	0.8	0.8	0.74	0.92	0.93	0.73	0.92	-0.11	0.74	0.84	0.06		-0.34	-0.5	0.99	-0.73	0.75	-0.37	0.72	-0.4	-0.45
Income Tax Expense	0.28	0.23	0.18	0.18	0.27	-0.14	-0.07	0.25	-0.06	0.22	0.26	0.23	0.37	-0.34		-0.39	-0.42	0.08	0.03	0.39	0.22	0.99	-0.55
Selling And Marketing Expenses	-0.77	-0.68	-0.71	-0.7	-0.75	-0.44	-0.56	-0.73	-0.57	-0.21	-0.75	-0.74	-0.57	-0.5	-0.39		-0.39	0.55	-0.53	-0.12	-0.5	-0.31	0.56
Net Income From Continuing Ops	0.67	0.68	0.74	0.74	0.66	0.91	0.9	0.66	0.9	-0.18	0.66	0.78	-0.02	0.99	-0.42	-0.39		-0.69	0.71	-0.4	0.67	-0.48	-0.38
Non Operating Income Net Other	-0.68	-0.63	-0.67	-0.67	-0.66	-0.61	-0.64	-0.67	-0.65	-0.16	-0.66	-0.71	-0.19	-0.73	0.08	0.55	-0.69		-0.51	-0.1	-0.65	0.14	0.42
Interest Income	0.89	0.94	0.93	0.94	0.91	0.88	0.89	0.9	0.9	-0.36	0.91	0.78	-0.07	0.75	0.03	-0.53	0.71	-0.51		-0.64	0.85	-0.04	-0.67
Net Interest Income	-0.23	-0.36	-0.34	-0.35	-0.28	-0.5	-0.44	-0.27	-0.43	0.7	-0.28	-0.14	0.49	-0.37	0.39	-0.12	-0.4	-0.1	-0.64		-0.25	0.43	0.01
Reconciled Depreciation	0.92	0.93	0.93	0.93	0.92	0.81	0.85	0.92	0.85	-0.07	0.92	0.87	0.14	0.72	0.22	-0.5	0.67	-0.65	0.85	-0.25		0.15	-0.87
Tax Provision	0.2	0.15	0.1	0.1	0.19	-0.2	-0.13	0.17	-0.12	0.25	0.18	0.16	0.33	-0.4	0.99	-0.31	-0.48	0.14	-0.04	0.43	0.15		-0.5
Non Recurring	-0.85	-0.85	-0.82	-0.82	-0.85	-0.58	-0.64	-0.85	-0.65	-0.07	-0.85	-0.78	-0.4	-0.45	-0.55	0.56	-0.38	0.42	-0.67	0.01	-0.87	-0.5

Click cells to compare fundamentals

Neurocrine Biosciences Account Relationship Matchups

Neurocrine Biosciences income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.5M	8.6M	10.9M	15.6M	21.3M	22.4M
Interest Expense	32M	32.8M	25.8M	7.1M	4.6M	7.4M
Selling General Administrative	354.1M	433.3M	583.3M	752.7M	851.6M	894.2M
Total Revenue	788.1M	1.0B	1.1B	1.5B	1.9B	2.0B
Gross Profit	780.7M	1.0B	1.1B	1.5B	1.8B	1.9B
Other Operating Expenses	561.5M	718.4M	925.7M	1.2B	1.6B	1.7B
Operating Income	219.1M	318.9M	196.9M	249M	250.9M	263.4M
Ebit	219.1M	327.5M	207.8M	249M	336.7M	353.5M
Research Development	200M	275M	328.1M	463.8M	565M	593.3M
Ebitda	226.6M	336.1M	218.7M	264.6M	358M	375.9M
Cost Of Revenue	7.4M	10.1M	14.3M	23.2M	39.7M	38.9M
Total Operating Expenses	554.1M	708.3M	911.4M	1.2B	1.6B	1.7B
Income Before Tax	46.5M	106.7M	101.4M	213.9M	332.1M	348.7M
Total Other Income Expense Net	(172.6M)	(56.3M)	(1.1M)	(35.1M)	81.2M	85.3M
Net Income	37M	407.3M	89.6M	154.5M	249.7M	262.2M
Income Tax Expense	9.5M	(300.6M)	11.8M	59.4M	82.4M	86.5M
Net Income From Continuing Ops	37.0M	407.3M	89.6M	154.5M	191M	200.6M
Non Operating Income Net Other	6.2M	(23.5M)	24.7M	(28M)	(25.2M)	(23.9M)
Net Income Applicable To Common Shares	37.0M	407.3M	89.6M	154.5M	177.7M	186.6M
Net Interest Income	(32.0M)	(32.8M)	(25.8M)	(7.1M)	(4.6M)	(4.8M)
Reconciled Depreciation	7.5M	8.6M	10.9M	15.6M	20M	10.8M
Tax Provision	9.5M	(300.6M)	11.8M	59.4M	60.8M	63.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurocrine Historical Income Statement

About Neurocrine Income Statement Analysis

Neurocrine Biosciences Income Statement Chart

Interest Expense

Other Operating Expenses

Total Operating Expenses

Neurocrine Biosciences income statement Correlations

Neurocrine Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neurocrine Biosciences income statement Accounts

Also Currently Popular

Additional Tools for Neurocrine Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Depreciation And Amortization
Total Operating Expenses	+ 1.0	Depreciation And Amortization
Gross Profit	+ 1.0	Total Revenue
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit

Non Recurring	- 0.87	Reconciled Depreciation
Non Recurring	- 0.85	Total Operating Expenses
Non Recurring	- 0.85	Research Development
Non Recurring	- 0.85	Other Operating Expenses
Non Recurring	- 0.85	Selling General Administrative
Non Recurring	- 0.85	Depreciation And Amortization